Ronald Levy, MD

Publication Details

• T cell antigen receptor vaccines for active therapy of T cell malignancies.

  Reddy SA, Okada C, Wong C, Bahler D, Levy R. Ann N Y Acad Sci. 2001: 941 97-105

  T cell lymphoproliferative disorders continue to be serious management problems, and so alternative therapeutic modalities are continuously being explored. One such strategy involves immunotherapy using the T cell receptor (TCR) as a target. Specifically we are attempting to develop a T cell receptor idiotype (TCR-Id) vaccine because the TCR-Id can serve as a tumor-specific antigen. In this article we will briefly review the rationale for TCR-Id vaccines, the preclinical models as developed in our laboratory, and a discussion of our current plans for a vaccine trial in mycosis fungoides.

  PubMedID: 11594586